You just read:

Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

News provided by

Satsuma Pharmaceuticals, Inc.

Aug 22, 2019, 13:26 ET